title: IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.
abstract: Studies of IL-28B genotype in patients with hepatitis C virus (HCV) genotype 2/3 infection have yielded conflicting results. The aim of this meta-analysis was to obtain a pooled odds ratio (OR) of the impact of IL-28B genotype on achieving sustained virologic response (SVR) in patients with HCV genotype 2/3 infection treated with pegIFN and ribavirin. A meta-analysis with a random effects model was performed, and study heterogeneity and publication bias were assessed. Forty-three percent of the Caucasians (11 studies) and 86% of Asians (five studies) had the favourable IL-28B genotype. In Caucasians, the pooled OR of SVR with the favourable IL-28B genotype was 1.36 (95%CI: 0.98-1.88, P = 0.07) in all patients and 1.55 (95%CI: 1.10-2.18, P = 0.01) in patients treated with pegIFN and ribavirin for ≥24 weeks. In Asians, the pooled OR of SVR in patients with the favourable IL-28B genotype was 1.99 (95%CI: 0.94-4.25, P = 0.07). The favourable IL-28B genotype was also significantly associated with rapid virologic response (RVR) in both groups (Caucasians: OR: 1.82, 95%CI: 1.12-2.96, P = 0.02; Asians: 2.39, 95%CI: 1.39-4.11, P = 0.002), as well as the likelihood of an SVR in a subgroup of 350 Caucasian patients without an RVR (OR: 3.29, 95%CI: 1.67-6.51, P = 0.001). The favourable IL-28B genotype is a statistically significant predictor of SVR and RVR in Caucasian patients treated with pegIFN and ribavirin for 24 weeks. In contrast, the favourable IL-28B genotype is associated with RVR, but not SVR in Asian HCV genotype 2 patients.
authors: Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA.
authors: A S
authors: AS
authors: Rangnekar
authors: R J
authors: RJ
authors: Fontana
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics; D020022:Genetic Predisposition to Disease; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000208:ethnology* / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D016017:Odds Ratio; D011092:Polyethylene Glycols; D020641:Polymorphism, Single Nucleotide; D017594:Publication Bias; D012254:Ribavirin / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D044465:White People / Q000235:genetics; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda
references: Gastroenterology. 2010 Sep;139(3):821-7, 827.e1
references: 20621700
references: Hepatology. 2011 Apr;53(4):1118-26
references: 21480318
references: Hepatology. 2011 Jan;53(1):7-13
references: 21254157
references: J Hepatol. 2011 Nov;55(5):980-8
references: 21354446
references: Nature. 2009 Sep 17;461(7262):399-401
references: 19684573
references: Clin Gastroenterol Hepatol. 2011 Apr;9(4):344-350.e2
references: 20728570
references: Eur J Gastroenterol Hepatol. 2011 Oct;23(10):931-5
references: 21900787
references: Gastroenterology. 2000 Nov;119(5):1385-96
references: 11054398
references: Hepatology. 2011 Oct;54(4):1433-44
references: 21898493
references: Ann Intern Med. 2004 Mar 2;140(5):346-55
references: 14996676
references: Dig Dis Sci. 2011 Nov;56(11):3296-304
references: 21994136
references: J Gen Virol. 2011 May;92(Pt 5):1071-1081
references: 21228123
references: J Infect Dis. 2011 Jun 15;203(12):1748-52
references: 21606533
references: J Med Virol. 2011 May;83(5):871-8
references: 21360545
references: N Engl J Med. 2005 Jun 23;352(25):2609-17
references: 15972867
references: Aliment Pharmacol Ther. 2012 Jul;36(2):104-14
references: 22612303
references: Aliment Pharmacol Ther. 2012 Jul;36(2):91-103
references: 22591106
references: J Hepatol. 2011 Mar;54(3):415-21
references: 21112657
references: Ann Intern Med. 2011 Oct 18;155(8):529-36
references: 22007046
references: Hepatology. 2011 Mar;53(3):746-54
references: 21374656
references: J Hepatol. 2011 Mar;54(3):408-14
references: 21112660
references: Aliment Pharmacol Ther. 2011 May;33(10):1162-72
references: 21443535
references: Am J Gastroenterol. 2011 Jul;106(7):1246-54
references: 21670772
references: J Gastroenterol Hepatol. 2011 Sep;26(9):1374-9
references: 21501223
references: Gastroenterology. 2005 Aug;129(2):522-7
references: 16083709
references: J Hepatol. 2004 Jun;40(6):993-9
references: 15158341
references: Hepatology. 2010 Jul;52(1):33-7
references: 20578254
references: N Engl J Med. 1999 Aug 19;341(8):556-62
references: 10451460
references: J Clin Epidemiol. 2010 May;63(5):513-23
references: 19595577